Pomahope 1mg


Pomahope 1mg is therapeutically categorized as an anti-neoplastic agent, which is active in multiple myeloma condition.
Pomahope 1mg capsules are used by the patients who are having a prescription specify by practiced medical oncologist.
Pomahope 1mg capsules are indicated in the patients who are already receiving Lenalidomide & proteasome inhibitors.
Pomahope 1mg capsules are endorsed by FDA and which is applicable as orally bioavailable.
Pomahope 1mg contains Pomalidomide which is act as anti-cancer agent.
Pomalidomide is a thalidomide analogue with efficient activities like;
Anti-angiogenesis, Immuno modulatory & anti-neoplastic activity
Pomahope 1mg capsules are available in various strengths like 1mg, 2mg, and 4mg.


The therapeutic indication of Pomahope 1mg is involved in condition like Multiple myeloma.
In this condition, Pomahope 1mg is utilized by consolidating with dexamethasone.
Pomahope 1mg cases are relevant in;
Patients formerly regarded with two treatments, for example, proteasome inhibitor and Lenalidomide.
Patients who are endured with illness movement condition
Pomahope 1mg treatment ought to be taken after inside 60 days in patients who are finished up the last treatment.

Dosage and administration

The most common indication of Pomahope is involved in the treatment of Multiple Myeloma condition.
The usual advised dose of Pomahope is 4mg tablet should be administered orally as once a day for cycles of 1 to 21 days for ensuing 28-day cycles.
During this treatment, Pomahope should be combinedly used with low dose of dexamethasone.
Dexamethasone should be administered on day 1, 8, 15 & 22 of every 28 days cycles.
The recommended dose of dexamethasone;
Higher than 75kg: The advised dose of dexamethasone is 20mg.
Dosage variation should be undergone during Pomahope treatment due to some hematological problems;
In Neutropenia condition;
ANC <500/mcL: The Pomahope treatment should be postponed and check the CBC weekly.
ANC ≥ 500/mcL: The Pomahope therapy should be continued by 3mg/day
For each successive drop <500/mcL: The Pomahope treatment should be postponed.
ANC ≥ 500/mcL: Promote the Pomahope therapy with 1mg/day.
Platelets count <25000/mcL: The Pomahope therapy should be postponed and check CBC
Platelets count ≥50000/mcL: The Pomahope treatment should be taken daily as 3mg/day.
Concomitant use of CYP1A2 with Pomahope; In case of combination of Pomahope with CYP1A2 causes increasing the plasma concentration of Pomalidomide and leads to cause increased adverse effects.
In this condition, reduce the dose of Pomahope.
In hepatic damaged patients;
Mild to moderate hepatic damage: The prescribed dose is 3mg of Pomahope should be taken.
Severe liver damage: The prescribed dose is 2mg of Pomahope should be taken.
In renal damaged patients;
In severe renal damage condition, the suggested dose is 3mg per day.

Mechanism Of Action

Pomalidomide has three noteworthy pharmacological exercises against tumor cells.
Pomalidomide includes in impeding the malignancy duplication and creates the apoptosis of disease cells.
Pomalidomide increase the T cell and natural killer cells interceding insusceptibility and forbid the development of professional provocative cytokines from monocytes.
Pomalidomide obstructs the new cell development. The official of Pomalidomide to dynamic site of focused cell causes restriction of ubiquitin ligase activity.


Pomahope 1mg peak plasma concentration time: 2 to 3 hours
Pomahope 1mg capsules should be administered with or without food.
Apparent volume of distribution 62 & 138L
Human plasma protein binding capacity is 12% & 44%.
Metabolism initiated by CYP1A2 & CYP3A4.
Clearance value 7 to 10L/hr.
Elimination occurs through feces & urine by 18% & 73%.
The unchanged form of Pomahope 1mg should be excreted via urine & feces by 2% & 8%.
Half-life period of Pomahope 1mg is 9.5 hours.


During Pomahope 1mg treatment, patients should be very cautiously taking the doses.
Two major life-threatening conditions are occurred at the time of therapy;
Venous & arterial thromboembolism:
Embryo fetal damage: To avoid such conditions, patient should be taken some precautions like;
Embryo fetal toxicity;
Pomahope 1mg should not be used during pregnancy period.
It comes under the category of X; may causes fetal toxic & leads to death.
Use some special contraceptive techniques for preventing pregnant during the treatment.
Pomahope 1mg may causes Teratogenicity, organogenesis & this may conclude as fetal damage.
Venous & arterial thromboembolism;
Deep vein thrombosis is the one of the major exposures occurs during the therapy of Pomahope 1mg.
To overcome the problem, thromboprophylaxis is initiated.
In case of combination of pembrolizumab with thalidomide analogues & dexamethasone causes increasing rate of mortality.
Especially in multiple myeloma adverse condition, this pembrolizumab with dexamethasone causes death rate in higher levels.
Hematological toxicity:
The most common hematological disorders are neutropenia, & thrombocytopenia which may occurs during the treatment using with Pomahope 1mg.
Reduce this type of effect by undergoing CBC counts frequently and monitor the patient’s manifestation due to this adverse.
Hepatic toxicity;
Hepatic associated adverse effects are mostly produced by elevation of hepatic enzymes levels.
This may lead to severe hepatic failure.
This condition may overcome by monitoring the patients hepatic function test regularly.
These neurological problems are produces during the Pomahope 1mg treatment by combining with dexamethasone.
The therapy should be postponed for some period like, toxicity grade alters to 0.
Second primary malignancies are most probably occurred in the patients who are receiving Pomahope 1mg capsules.
Tumor lysis syndrome;
During this adverse condition, Pomahope 1mg therapy should be interrupt and follow the general supportive measures for the patients.
Then the signs & symptoms occur due to this TLS should be monitored.

Drug Interaction

The concomitant use of Pomahope 1mg with CYP1A2 potent inhibitors like Fluvoxamine which will lead to elevate the plasma concentration of Pomalidomide and increases the adverse effects related to the pomalidomide.
Stop the condition by reducing the Pomahope 1mg dosage.


Pregnancy category of Pomahope 1mg is categorized as X
X means causes fetal damage during the Pomahope 1mg treatment.
Pomahope 1mg causes embryo fetal damage.


Breast feeding should not be recommended.


The potency & effectiveness of Pomahope 1mg should not be evaluated.


Dose change of Pomahope 1mg ought not to be suggested. Geriatric patients with time of over 65 years ought to be knowledgeable about pneumonia.

Missed Dose

If a dose is missed, then have the drug immediately before the next dose times arrives or skip the missed dose and follow regular schedule. Avoid two doses taking, consult with doctor.


Pomahope 1mg capsules container should be keep in a temperature of 20oC to 25oC.
Do not store the container in light
Protect from moisture & heat.


Pomahope 1mg is contraindicated to pregnant women.
Some anaphylactic reactions are occurring because patients are contraindicated to the component in the Pomahope 1mg capsules.

Connect With Us

Prescription Medication Policy

1. Anti-Cancer-Drugs.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. Anti-Cancer-Drugs.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the Anti-Cancer-Drugs.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. Anti-Cancer-Drugs.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Anti-Cancer-Drugs.com
6. At Anti-Cancer-Drugs.com, a Caregiver can order prescription medicines on your behalf.